Quantcast
Last updated on April 19, 2014 at 18:42 EDT

Latest Personalized medicine Stories

2013-09-30 04:22:27

ANTWERP, Belgium, September 30, 2013 /PRNewswire/ -- Multiplicom NV, a specialist in the development, production and commercialization of innovative molecular genetic tests based on massively parallel sequencing (MPS), today announces that it is launching three new somatic mutation detection kits which will enable users to implement personalized cancer treatment at an unprecedented level. The new kits enable PCR amplification of genes known to be frequently mutated in...

2013-09-29 23:01:19

The report “Biomarkers Market – ([Discovery Technologies - Proteomics, Genomics, Imaging, Bioinformatics], Validation Services, Applications [drug development, personalized medicine], Diseases [Oncology, Cardiology, Neurology]) – Global Trends & Forecasts (2013 – 2018)” says global biomarkers market shows a high growth potential and accounts for $17.5 billion in 2013. Dallas, Texas (PRWEB) September 29, 2013 A biomarker is an identifiable and measurable characteristic, which...

2013-09-29 00:21:19

Embargo: 6:01 pm ET, Sunday, September 29, 2013 AMSTERDAM, Sept. 29, 2013 /PRNewswire/ -- Caris Life Sciences announced today data from two studies presented at the 2013 European Cancer Congress (ECC 2013), which demonstrate the potential of evidence-guided molecular profiling to immediately improve the treatment of patients with hard-to-treat cancers, including cancers of unknown primary (CUP) origins as well as rare tumors and cancers that have been refractory to treatment....

2013-09-27 23:20:55

The report “Cancer/Tumor Profiling Market [Applications (Personalized Medicine, Diagnostics, Biomarker Discovery, Prognosis, Research), Technologies (NGS, QPCR, IHC, FISH/CISH, Microarray), Segments: Genomics, Proteomics, Metabolomics, Epigenetics)] 2013 – 2018” says cancer/tumor profiling market is valued at $14.99 billion in 2013 and is expected to reach $35.03 billion by 2018. Dallas, Texas (PRWEB) September 27, 2013 Cancer/Tumor profiling is a promising market and is witnessing...

2013-09-26 08:27:11

DALLAS, September 26, 2013 /PRNewswire/ -- The "CANCER/TUMOR PROFILING MARKET [Applications (Personalized Medicine, Diagnostics, Biomarker Discovery, Prognosis, Research), Technologies (NGS, QPCR, IHC, FISH/CISH, Microarray), Segments: Genomics, Proteomics, Metabolomics, Epigenetics)] 2013 - 2018", report analyzes and studies the major market drivers, restraints, and adoption potential in North America, Europe, Asia, and Rest of the World. Browse market 22 data tables...

2013-09-25 12:28:28

New Leadership Will Implement Labmatrix(TM) Software to Create Next Generation Biobanking Solutions MORRISVILLE, N.C., Sept. 25, 2013 /PRNewswire/ -- Gentris® Corporation (www.gentris.com), a global leader in pharmacogenomics and biorepository solutions, announced today that it has partnered with BioFortis to integrate its Labmatrix(TM) and Qiagram(TM) software into Gentris' laboratory operations. The Labmatrix(TM) and Qiagram(TM) software will provide an advanced platform for...

2013-09-25 08:28:47

NICE's Recommendation of Oncotype DX® Test is an Important Milestone in Delivering Personalized Medicine to More UK Patients REDWOOD CITY, Calif., Sept. 25, 2013 /PRNewswire/ -- Genomic Health, Inc. today announced that the National Institute for Health and Care Excellence (NICE) in the United Kingdom has issued its final guidance recommending Oncotype DX(®) as the only multi-gene breast cancer test for use in clinical practice to guide chemotherapy treatment decisions for patients...

2013-09-25 08:25:03

With the Potential Launch of New Targeted Oncology Agents, Demonstrating Innovation and Proving Value Will be Critical, According to a New Report from Decision Resources BURLINGTON, Mass., Sept. 25, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, despite being a therapeutic area with high unmet need and a rich development pipeline, the barriers to market access for oncology therapies...

2013-09-23 16:24:12

New Cytochrome P450 2C19 Assay Helps Physicians Optimize Individual Patient Care AUSTIN, Texas, Sept. 23, 2013 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced it has received U.S. FDA and European clearance for a comprehensive genotyping assay, xTAG® CYP2C19 Kit. This new test enables a personalized approach to aid physicians in determining patient treatment plans based on certain genetic variants of the P450 2C19 gene. (Logo:...

2013-09-23 12:25:39

DALLAS, September 23, 2013 /PRNewswire/ -- The "Biomarkers Market - ([Discovery Technologies - Proteomics, Genomics, Imaging, Bioinformatics], Validation Services, Applications [drug development, personalized medicine], Diseases [Oncology, Cardiology, Neurology]) - Global Trends & Forecasts (2013 - 2018)", analyzes & studies the major market drivers, restraints, and opportunities in North America, Europe, Asia-Pacific, & Rest of the World (ROW). Browse 131...